The German pharmaceuticals group Merck KGaA has started the reorganization of its main drug-sector businesses in France. Its two French subsidiaries, Lipha and Merck Clevenot, are being merged into a new company designated Merck Lipha, which will be based in Lyon, France. Lipha produces pharmaceuticals while Merck Clevenot, in addition to prescription drugs, makes equipment for laboratory analysis, reagents for diagnosis and cosmetics raw materials.
The president of the new company will be Jean-Noel Treilles, currently president of Lipha, with Karl Heinz Peter, president of Merck Clevenot, as vice president. The aim of the reorganization is to reduce the number of areas of group management responsibility in France.
Despite the business revival reported by Merck KGaA in the first six months of 1996 (Marketletter August 5), analysts Mark Tracey and John Murphy at Goldman Sachs are reiterating their rating of the firm as a market underperformer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze